News brief­ing: New senes­cent cell play launch­es with $12M; Jun­shi leads Se­ries C+ in­fu­sion for Chi­nese syn­thet­ic lethal­i­ty play­er

The idea of tar­get­ing senes­cent cells to treat age-re­lat­ed dis­eases is con­tin­u­ing to gath­er steam, and Khosla Ven­tures is help­ing get the lat­est play go­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER